Farydak patents expiration

FARYDAK's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7989494 SECURA Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
Jan, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8883842 SECURA Use of HDAC inhibitors for the treatment of myeloma
Jun, 2028

(4 years from now)

Farydak is owned by Secura.

Farydak contains Panobinostat Lactate.

Farydak has a total of 2 drug patents out of which 0 drug patents have expired.

Farydak was authorised for market use on 23 February, 2015.

Farydak is available in capsule;oral dosage forms.

Farydak can be used as treatment of multiple myeloma, in combination with bortezomib and dexamethasone.

The generics of Farydak are possible to be released after 13 June, 2028.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 23, 2022

Drugs and Companies using PANOBINOSTAT LACTATE ingredient

Market Authorisation Date: 23 February, 2015

Treatment: Treatment of multiple myeloma, in combination with bortezomib and dexamethasone


More Information on Dosage

FARYDAK family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic